What is BHRT and how do I know if I need it?

Short answer BHRT = bioidentical hormone replacement therapy. It means replacing hormones (usually estrogen, progesterone, sometimes testosterone or thyroid-related hormones) with compounds that are chemically identical to the hormones your body makes. BHRT is used to treat symptoms of menopause/perimenopause, surgical menopause, and some cases of low sex hormones. Whether you “need” it depends on your symptoms, medical history, test results, and risk tolerance — and should be decided with a clinician.

What BHRT actually is

• “Bioidentical” means the hormone’s chemical structure matches human hormones (e.g., 17β-estradiol, micronized progesterone).
• BHRT can be delivered as FDA‑approved products (patches, gels, tablets, vaginal rings/tablets) or as custom-compounded products from compounding pharmacies. FDA‑approved bioidentical products have standardized dosing and safety data; compounded products are less regulated and have more variability.

Who may benefit Common indications:

• Moderate–severe hot flashes and night sweats
• Vaginal dryness, painful intercourse, urinary symptoms from estrogen deficiency
• Significant sleep disturbance, mood changes, low libido, fatigue related to hormone loss
• Women with early/surgical menopause or very low measured hormones

How to know if you need BHRT

1. Assess symptoms: Keep a symptom diary (hot flash frequency/severity, sleep, mood, sexual changes).
2. See a clinician experienced in menopause/endocrinology (OB‑GYN, primary care with menopause training, or an endocrinologist).
3. Medical evaluation: review medical history (breast cancer, clotting/stroke history, heart disease, liver disease, smoking), medications, family history.
4. Tests: providers may order baseline labs (TSH, fasting lipids and glucose, possibly serum estradiol/testosterone, FSH) and screening tests (mammogram, pelvic exam). Note: sex hormones fluctuate, so labs are an adjunct — decisions are often symptom-driven.
5. Discuss risks/benefits and alternatives; if chosen, start the lowest effective dose and plan monitoring.

Risks and important contraindications

• Contraindicated or used with caution in people with current or past hormone‑sensitive cancers (some breast or endometrial cancers), active or history of venous thromboembolism, uncontrolled cardiovascular disease, or liver disease.
• Side effects vary by route and hormone used (bloating, breast tenderness, mood changes, risk changes for clotting, stroke, and possibly some cancers depending on regimen).
• Compounded preparations lack the same regulatory oversight and long‑term safety data.

Monitoring

• Reassess symptoms, side effects, blood pressure, weight.
• Regular mammography and clinical exams as recommended.
• If you have a uterus and take systemic estrogen, you need appropriate progestogen to reduce endometrial cancer risk (unless you’ve had a hysterectomy). Labs may be repeated as needed.

Alternatives

• Vaginal estrogen for local genitourinary symptoms (low systemic exposure).
• Nonhormonal options for hot flashes: paroxetine (Brisdelle — FDA‑approved for hot flashes), SSRIs/SNRIs (e.g., venlafaxine), gabapentin, clonidine, behavioral measures (cooling, pacing, sleep hygiene). Bone‑directed therapies if osteoporosis is a concern.

Specific brands and services (brief)

• Climara or Vivelle‑Dot (estradiol patches) — FDA‑approved transdermal estradiol patches with predictable dosing and extensive safety data. Good option when avoiding first‑pass liver effects.
• Prometrium (micronized progesterone) — FDA‑approved bioidentical progesterone; recommended when progestogen is needed because it’s well studied.
• Vagifem (vaginal estradiol tablet) or Estring (vaginal ring) — FDA‑approved for vaginal symptoms; effective locally with low systemic exposure.
• Brisdelle (low‑dose paroxetine) — nonhormonal, FDA‑approved for hot flashes when hormones are contraindicated.
• BioTE or SottoPelle — companies offering pellet BHRT (subcutaneous hormone pellets). These are popular but carry specific risks (infection, pellet extrusion) and have less rigorous clinical trial data; discuss carefully with your clinician.
• For evaluation and evidence‑based care: consider clinics or resources associated with the North American Menopause Society (NAMS), Mayo Clinic, or Cleveland Clinic — they follow established guidelines and can help you weigh risks and options.
• If using compounded hormones, use a state‑licensed compounding pharmacy with accreditation (ask your clinician which pharmacies they trust and whether the pharmacy adheres to USP standards).

Next steps I recommend

1. Track your symptoms for 2–4 weeks.
2. Book an appointment with a clinician experienced in menopause/hormone care (ask if they follow NAMS or Endocrine Society guidance).
3. Bring your symptom notes, medical history, and questions about risks/alternatives.
4. If BHRT is started, plan baseline tests and a follow‑up schedule to reassess benefits and safety.

If you’d like, tell me your main symptoms and medical history (age, whether you still have a uterus, prior breast or clotting history, smoking, major illnesses) and I can help you think through whether BHRT is likely to be considered and what questions to ask a clinician.